
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
13/11/2026
0:00
1:30
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Otros episodios de "Applied Clinical Trials"



No te pierdas ningún episodio de “Applied Clinical Trials”. Síguelo en la aplicación gratuita de GetPodcast.








